A clinical trial testing two drugs against the Bundibugyo ebolavirus, which is driving a fast-moving outbreak in Central Africa, is set to begin next week, World Health Organization officials said Wednesday.
The clinical trial — which will test both Gilead Sciences’ antiviral drug remdesivir and MappBio’s monoclonal antibody MBP-134 — will be conducted in the Democratic Republic of the Congo. The trial is designed to test whether either of the therapies is effective against this form of Ebola, and whether using the two in combination would be a more effective way to combat the disease.
